// App-Quantinova.ai

920-04 : BIVALIRUDIN VERSUS HEPARIN WITH OR WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN STEMI PATIENTS UNDERGOING PRIMARY PCI: A POOLED ANALYSIS OF PATIENT-LEVEL DATA FROM THE HORIZONS-AMI AND EUROMAX TRIALS

Researchers

Presenter

  • Philippe Gabriel Steg

Principal Investigators

  • Roxana Mehran

  • Patrick Goldstein

  • Bernhard Witzenbichler

  • Arnoud va-t Hof

  • Giulio Guagliumi

  • Christian W. Hamm

  • Philippe Genereux

  • Peter Clemmensen

  • Helen Parise

  • Stuart Pocock

Medical Centers

  • Assistance Publique, Hopitaux de Paris, Hopital Tenon, Paris, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Acute Coronary Syndromes

  • Thrombocytopenia

  • Venous thrombosis

  • Coronary Artery Disease

  • Stroke

Biomarkers

  • Glycosylphosphatidylinositol

Drug/Treatment

  • Bivalirudin

  • Heparin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved